Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Safety, Tolerability, and Pharmacokinetic Study of Single and Multiple Ascending Dose of YY524051 Tablets in Healthy Adults.

13 november 2026 bijgewerkt door: Beijing Baheal Wisart Medical Research Co., Ltd

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral YY524051 Tablets in Healthy Participants

This is a Phase 1 study to evaluate the safety, tolerability, and how the body processes an investigational drug called YY524051 tablets in healthy participants.

Studie Overzicht

Toestand

Nog niet aan het werven

Gedetailleerde beschrijving

This is a single-center Phase 1, randomized, double-blind, placebo controlled, first-in-human (FIH) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of an investigational drug called YY524051 tablets in healthy adult participants.

The study is divided into two parts:

Single Ascending Dose (SAD) part: Participants will receive a single dose of the drug to see how the body handles it and to determine a safe dose level. A staggered dosing schedule will be used, where a few "sentinel" participants will be dosed first to ensure safety before the rest of the cohort receives the drug. A food-effect (FE) assessment will be nested at a selected dose level after fasting dosing during escalation, and a clinical QT/QTc (CQTc) assessment will be embedded within selected SAD cohorts.

Multiple Ascending Dose (MAD) part: Participants will take the drug repeatedly over several days to assess accumulation and steady-state in the body and to further evaluate its safety.

Participants will be randomly assigned to receive either YY524051 tablets or a placebo (placebo tablet containing no active ingredient). The study is "double-blind," meaning neither the participants nor investigators will know who is receiving the real drug.

The information gathered from this study will help researchers understand the best way to give this drug, characterize its PK profile, and determine a safe dose for future studies in patients.

Studietype

Ingrijpend

Inschrijving (Geschat)

78

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Beijing, China
        • Peking University Third Hospital

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 45 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

Participants must meet ALL of the following criteria to be eligible for enrollment:

  • Healthy participants, male or female (the ratio of males to females will be kept as balanced as possible).
  • Age between 18 and 45 years (inclusive). Body weight ≥ 50 kg for males and ≥ 45 kg for females. Body Mass Index (BMI) between 19.0 and 28.0 kg/m² (inclusive). BMI = weight (kg) / height² (m²).
  • Able to understand the informed consent form, and voluntarily participate and sign the informed consent form.

Exclusion Criteria:

Participants who meet ANY of the following criteria will be excluded from the study:

  • History of drug allergy, or known allergy to the investigational product or any of its excipients (microcrystalline cellulose, mannitol, croscarmellose sodium, povidone, magnesium stearate, film coating premix (gastric-soluble), sodium stearyl fumarate, lactose);
  • History of or current clinically significant diseases in the circulatory, endocrine, nervous, digestive, respiratory, hematological, immunological, psychiatric, or metabolic systems, as determined by the investigator;
  • History of drug addiction; history of alcohol abuse within 6 months prior to screening (defined as consuming more than 14 standard units of alcohol per week [1 unit = 360 mL of beer, 45 mL of 40% spirits, or 150 mL of wine]); average daily cigarette consumption ≥ 5 cigarettes within 3 months prior to screening; positive urine drug screen or positive alcohol breath test at screening; or inability to comply with the prohibition of smoking/alcohol during the study period;
  • History of cardiovascular or cerebrovascular surgery; history of any surgery affecting drug absorption, distribution, metabolism, or excretion; severe trauma or surgery within 6 months prior to screening; or planned surgery during the study period;
  • Positive results for any of the following: Hepatitis B surface antigen (HBsAg), Hepatitis C virus antibody (HCVAb), Treponema pallidum particle agglutination (TPPA), or Human Immunodeficiency Virus (HIV) antibody;
  • Positive pregnancy test for female participants;
  • Breastfeeding female participants; female participants who refuse to use effective non-pharmacological contraceptive measures (e.g., abstinence, intrauterine device) or have egg donation plans from signing the informed consent until 90 days after the last dose; male participants who refuse to commit to no reproductive or sperm donation plans or refuse to use effective physical contraceptive measures, or have sperm donation plans from signing the informed consent until 90 days after the last dose;
  • Abnormalities in physical examination, laboratory tests, vital signs, echocardiography, abdominal ultrasound, or chest X-ray that are clinically significant as determined by the investigator and may affect the evaluation of study endpoints;
  • Blood pressure ≥ 140/90 mmHg or < 90/50 mmHg; heart rate < 50 beats/min or > 100 beats/min;
  • Clinically significant abnormalities on 12-lead electrocardiogram (ECG) as determined by the investigator, including: Prolonged QT interval: QTcF > 450 msec (males) or > 470 msec (females); PR interval > 200 msec; QRS interval > 120 msec;
  • Consumption of excessive tea, coffee, or caffeine-containing beverages (≥ 8 cups per day, 1 cup = 250 mL) daily within 3 months prior to screening; or habitual consumption of any xanthine-rich beverages or foods (e.g., caffeine, theophylline, theobromine) or fruits/foods affecting metabolic enzymes (e.g., grapefruit, pomelo, starfruit, mango) that cannot be abstained from during the study period;
  • Special dietary requirements or inability to comply with a standardized diet;
  • Difficulty swallowing tablets;
  • Inability to tolerate venipuncture, history of hemophobia/needle phobia, or poor vascular conditions making blood collection difficult;
  • Use of any drugs that inhibit or induce hepatic drug-metabolizing enzymes within 28 days prior to screening; or use of any prescription drugs, over-the-counter drugs, herbal medicines, or dietary supplements within 2 weeks (or 5 half-lives, whichever is longer) prior to screening;
  • Participation in any clinical trial within 3 months prior to screening; or still within 5 half-lives of an investigational drug from a previous clinical trial at screening;
  • History of blood donation or significant blood loss (≥ 400 mL) within 3 months prior to screening or between screening and first dose; history of blood transfusion within 3 months; or plans to donate blood during the study period;
  • Poor compliance or any other conditions that make the participant unsuitable for the study as judged by the investigator.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Sequentiële toewijzing
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Placebo-vergelijker: Placebo

Matching placebo tablets will be administered orally to participants in the control groups. In the SAD phase (initially planned up to 5 cohorts), a single dose will be given once in the morning under fasting conditions. In the MAD phase (initially planned up to 3 cohorts), placebo will be administered once daily in the morning for 7 consecutive days. The actual number of cohorts may be adjusted based on the safety and tolerability data reviewed by the Safety Review Committee (SRC)

Matching placebo.

Experimenteel: YY524051 tablets

YY524051 tablets will be administered orally to participants in the treatment groups. In the SAD phase (initially planned up to 5 cohorts), single ascending doses will be given once in the morning under fasting conditions. In the MAD phase (initially planned up to 3 cohorts), multiple ascending doses will be administered once daily in the morning for 7 consecutive days. The actual number of cohorts and dose levels may be adjusted based on the safety and tolerability data reviewed by the Safety Review Committee (SRC).

YY524051 tablets administered orally

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Incidence, severity, and causality of adverse events (AEs) and serious adverse events (SAEs)
Tijdsspanne: SAD: Day1 to Day 8 MAD: Day1 to Day 14

Safety and Tolerability as assessed by AEs and SAEs

SAD: Day1 to Day 8 MAD: Day1 to Day 14

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Tmax
Tijdsspanne: Pre-dose to 48 hours post-dose

Peak time: The time required to reach peak concentration after administration

Pre-dose to 48 hours post-dose
Cmax
Tijdsspanne: Pre-dose to 48 hours post-dose

Peak concentration: The highest blood concentration after administration

Pre-dose to 48 hours post-dose
AUC
Tijdsspanne: Pre-dose to 48 hours post-dose

Area under the drug time curve: The area surrounded by the blood concentration curve to the time axis.

Pre-dose to 48 hours post-dose
t1/2
Tijdsspanne: Pre-dose to 48 hours post-dose

Terminal elimination half-life: The time required for the terminal phase blood concentration to decrease by half

Pre-dose to 48 hours post-dose

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 december 2026

Primaire voltooiing (Geschat)

1 december 2027

Studie voltooiing (Geschat)

1 december 2027

Studieregistratiedata

Eerst ingediend

13 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

13 november 2026

Eerst geplaatst (Werkelijk)

18 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 november 2026

Laatste update ingediend die voldeed aan QC-criteria

13 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • YY524051-I-01
  • CTR20264102 (Andere identificatie: CDE,NMPA)

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren